For several years, herbal medicines have been increasingly consumed by
patients without prescription. They are traditionally innocuous but a
s medicinal products they require drug surveillance in order to identi
fy their risks. However, the first concern is to give them a legal sta
tus, to evaluate their efficacy and to control their safety. Published
data show that the risk is due either to a contaminant or to an added
drug or falsification. Since 1985, the Regional Pharmacovigilance Cen
tres have received about 341 reports of undesirable effects due to her
bal medicines : among them 30 cases of hepatitis were reported associa
ted with germander which has been not withdrawn from the French market
. This example well illustrates the role of the national system and it
s responsibility for collecting and evaluating ADRs due to herbal medi
cines.